Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06103695 · ClinicalTrials.gov registry record · Phase 4
Vtama in Psoriasis Patients Being Treated With Biologics.
A Phase 4 study, sponsored by Psoriasis Treatment Center of Central New Jersey.
- Completed
- Registry status
- Phase 4
- Development phase
- 30
- Enrollment target
NCT06103695 is a Phase 4 study that has completed, run by Psoriasis Treatment Center of Central New Jersey. The registered enrollment target is 30 participants.
The verdict
NCT06103695, a Phase 4 study, has completed, sponsored by Psoriasis Treatment Center of Central New Jersey.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 30 participants
- Enrollment target
Study Summary
Open label study to assess 12 weeks of add-on VTAMA® (tapinarof) Cream, 1% QD in patients with ≥3% BSA who have received biologic therapy for at least 24 weeks.
Interventions
- DRUG Tapinarof
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2023-02-27 |
| Est. Completion | 2023-10-18 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06103695
The ClinicalTrials.gov registry entry for NCT06103695 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Psoriasis Treatment Center of Central New Jersey, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tapinarof is the first listed.
NCT06103695 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06103695 about?
NCT06103695 is a clinical study titled "Vtama in Psoriasis Patients Being Treated With Biologics.". Open label study to assess 12 weeks of add-on VTAMA® (tapinarof) Cream, 1% QD in patients with ≥3% BSA who have received biologic therapy for at least 24 weeks.
What is the current status of trial NCT06103695?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 30 participants. The study started on 2023-02-27. Estimated completion is 2023-10-18.
What interventions are being tested in trial NCT06103695?
The interventions under investigation include: Tapinarof (DRUG).
Who is sponsoring clinical trial NCT06103695?
This trial is sponsored by Psoriasis Treatment Center of Central New Jersey, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.